Best Practices in Cardiac Safety Data Collection Before and After the thorough QT Trial Webinar June 7



r. Jeffrey Litwin will provide current insights into the differences between Phase I versus Phases II-III and Phase IV cardiac safety testing.

Chicago, IL May 29, 2007 -- Xtalks and eResearchTechnology are pleased to present the web conference Best Practices in Cardiac Safety Data Collection Before and After the thorough QT Trial, scheduled for June 7, 2007.

Recent years have seen a dramatic increase in focus on cardiac safety in new drug development. ICH E14 guidance was finalized in May 2005. An important component of the guidance is the requirement of the Thorough QT Trial (TQT) in the development of new drug candidates.

Dr. Jeffrey Litwin will provide current insights into the differences between Phase I versus Phases II-III and Phase IV cardiac safety testing. He will address common ECG collection practices at sites versus best practices and when one approach may be preferred over another. Dr. Litwin will address the impact of the TQT on Phase III programs and provide additional discussion on ECG data considerations beyond QTc. Dr. Litwin will address how implementation of best practices ensures data quality and consistency and reduces data evaluation time.

There is no cost to attend, register at: http://www.xtalks.com/csdata.ashx         

Pre-web Cast Questions
>What is the difference between cardiac safety assessments in Phase I versus Phase II-III and Phase IV
>When and how many ECGs should be acquired and how should ECG measurements and interpretations be conducted
>How should ECGs be acquired at clinical sites and what is the role of local interpretation of ECG data
>How should ECG data be analyzed

The Best Practices in Cardiac Safety Data Collection Before and After the thorough QT Trial web conference takes place June 7, 2007, from 10:00am - 12:00pm EDT.

Register at: http://www.xtalks.com/csdata.ashx         

Jeffrey S. Litwin, M.D., F.A.C.C., Executive VP, Chief Medical Officer, eResearchTechnology, Inc.

Jeffrey Litwin, M.D. is a board certified Internist and Cardiologist. He is currently an Executive VP and Chief Medical Officer for eResearchTechnology which he joined in 2000. He provides consultation to the Biopharmaceutical Industry for the design and conduct of cardiac safety trials and to the Device Industry for the design of ECG and Holter technologies.

About eResearchTechnology:
eResearchTechnology (eRT) provides technology and services that enable life sciences industries to collect, interpret and distribute cardiac data accurately and efficiently. eRT is a leading provider of centralized electrocardiographic (ECG) services and supports the full-range of studies from single center to multi-center global trials across all therapeutic groups. eRT is an industry leader for Thorough QTc Trials (TQT), having completed significantly more than any other core lab. www.ertconsultant.com

About Xtalks:
Xtalks is part of The Honeycomb Worldwide Group of Companies. Honeycomb Worldwide creates peer-to-peer business-oriented social networking communities, connecting senior level executives by delivering content through new and established media channels and is currently ranked 15th on the Profit Hot 50 List of emerging Canadian companies. www.honeycombworldwide.com.

For more information on this conference or Xtalks in general, or to enquire about speaking opportunities or sponsoring future events, visit www.xtalks.com or contact Karen Anderson, Chief Marketing Officer, at phone: 312-977-1166, x. 1209.

Register at http://www.xtalks.com/csdata.ashx





Best Practices in Cardiac Safety Data Collection Before and After the thorough QT Trial Webinar June 7